Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
- Resource Type
- Article
- Source
- In
Clinical Therapeutics February 2019 41(2):280-290 - Subject
- Language
- ISSN
- 0149-2918